Get the Stockscreener App
0.00
100.00%
-54.65
After Hours:
54.70
54.70
+
Akero Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$54.65
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$4.50B
Revenue:
-
Net Income/Loss:
$-269.44M
P/E Ratio:
0.00
EPS:
-3.75
Net Cash Flow:
$-262.63M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$57.35
Akero Therapeutics Inc Stock (AKRO) Company Profile
Name
Akero Therapeutics Inc
Sector
Industry
Phone
650-487-6488
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Compare AKRO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKRO
Akero Therapeutics Inc
|
0.00 | 4.50B | 0 | -269.44M | -262.63M | -3.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.59 | 118.41B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
744.12 | 80.02B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.77 | 43.52B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.80 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.29 | 32.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Aug-04-25 | Initiated | TD Cowen | Buy |
| Jan-30-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-27-25 | Reiterated | H.C. Wainwright | Buy |
| Nov-18-24 | Initiated | Citigroup | Buy |
| Apr-22-24 | Resumed | BofA Securities | Neutral |
| Sep-19-23 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-23 | Initiated | UBS | Buy |
| Jan-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-14-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Initiated | Guggenheim | Buy |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Jul-20-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-07-20 | Initiated | Chardan Capital Markets | Buy |
| Jul-01-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-02-20 | Initiated | H.C. Wainwright | Buy |
| Feb-10-20 | Initiated | Canaccord Genuity | Buy |
| Jul-15-19 | Initiated | Evercore ISI | Outperform |
| Jul-15-19 | Initiated | JP Morgan | Overweight |
| Jul-15-19 | Initiated | Jefferies | Buy |
| Jul-15-19 | Initiated | ROTH Capital | Buy |
View All
Akero Therapeutics Inc Stock (AKRO) Latest News
Signal Recap: How does Akero Therapeutics Inc score in quality rankings2026 Biggest Moves & Long-Term Safe Investment Ideas - baoquankhu1.vn
Published on: 2026-03-11 23:57:58 - baoquankhu1.vn
Panic Selling: What is Akero Therapeutics Incs revenue forecastWeekly Market Summary & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Treasury Yields: Is Akero Therapeutics Inc stock good for income investorsEarnings Recap Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Understanding Momentum Shifts in (AKRO) - Stock Traders Daily
What’s Driving The Super Rally In Akero Shares On Thursday Morning? - Stocktwits
Published on: 2026-03-01 05:11:32 - baoquankhu1.vn
Aug Chart Watch: Can Akero Therapeutics Inc maintain sales growthDollar Strength & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Short Covering: Does Akero Therapeutics Inc meet Warren Buffetts criteriaPortfolio Gains Summary & Risk Controlled Swing Alerts - baoquankhu1.vn
Macro Review: Is Akero Therapeutics Inc stock influenced by commodity pricesGap Down & AI Forecasted Entry/Exit Points - baoquankhu1.vn
AKRO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Akero Therapeutics Inc. stock a falling knife or bargain buyRecession Risk & AI Powered Market Trend Analysis - mfd.ru
Resistance Check: Can Akero Therapeutics Inc stock outperform in a bear marketJuly 2025 Selloffs & Precise Buy Zone Identification - baoquankhu1.vn
Merger Talk: Is Akero Therapeutics Inc backed by strong institutional buying2025 Short Interest & AI Based Buy and Sell Signals - baoquankhu1.vn
Is Akero Therapeutics Inc. backed by strong institutional buyingJuly 2025 Fed Impact & Stock Market Timing Techniques - mfd.ru
Akero Therapeutics (NASDAQ: AKRO) holder Janus Henderson now at 4.1% - Stock Titan
Weekly Earnings: Does Akero Therapeutics Inc have consistent dividend growthMarket Risk Summary & Scalable Portfolio Growth Methods - baoquankhu1.vn
Growth Value: Can Solid Biosciences Inc withstand a market correctionMarket Sentiment Review & Smart Allocation Stock Reports - baoquankhu1.vn
RTW Investments exits Akero Therapeutics (AKRO), reporting 0.0% ownership - Stock Titan
Can Akero Therapeutics Inc. maintain its current growth rateJuly 2025 PreEarnings & High Yield Equity Trading Tips - mfd.ru
Pullback Watch: Should you avoid Akero Therapeutics Inc stock right now2025 Key Lessons & High Accuracy Trade Alerts - baoquankhu1.vn
What’s Akero Therapeutics Inc.’s historical returnPortfolio Performance Report & Daily Risk Controlled Trade Plans - mfd.ru
Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero - MSN
Aug Wrap: Is Akero Therapeutics Inc. stock showing strong momentumPrice Action & Safe Entry Point Alerts - mfd.ru
Can Akero Therapeutics Inc. maintain sales growthCPI Data & Daily Entry Point Trade Alerts - mfd.ru
Analyst Downgrade: Is Akero Therapeutics Inc stock good for income investors2025 Investor Takeaways & High Yield Stock Recommendations - baoquankhu1.vn
TD Cowen Initiates Coverage of Akero Therapeutics (AKRO) with Buy Recommendation - MSN
Is Akero Therapeutics Inc. stock affected by interest rate hikesJuly 2025 WrapUp & AI Powered Market Entry Strategies - mfd.ru
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating Growth in Biotechnology with a 3.39% Potential Upside - DirectorsTalk Interviews
Behavioral Patterns of AKRO and Institutional Flows - Stock Traders Daily
Analyst Calls: Is Akero Therapeutics Inc stock showing strong momentumPortfolio Growth Summary & AI Powered Market Trend Analysis - baoquankhu1.vn
Aug Movers: Is Akero Therapeutics Inc. stock influenced by commodity prices2025 Support & Resistance & Momentum Based Trading Ideas - mfd.ru
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring the 3.39% Potential Upside in Biotech Innovation - DirectorsTalk Interviews
Does Akero Therapeutics Inc. have consistent dividend growth2025 Price Targets & Weekly Watchlist for Hot Stocks - mfd.ru
Investment Report: Will Akero Therapeutics Inc outperform the market in YEARJuly 2025 Analyst Calls & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Income Plays: Is INTU a stock for growth or value investorsJuly 2025 Rallies & Expert-Curated Trade Recommendations - baoquankhu1.vn
Guidance Update: What is the earnings history of Akero Therapeutics Inc2025 Volume Leaders & Safe Capital Growth Tips - baoquankhu1.vn
(AKRO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Quarterly Trades: How does ProShares Trust ProShares UltraPro Short QQQ perform in inflationary periodsJuly 2025 Action & High Accuracy Buy Signal Tips - baoquankhu1.vn
In Vivo’s Deals Of The Year: Cast Your Vote! - Citeline News & Insights
RSI Check: Does Akero Therapeutics Inc meet Warren Buffetts criteriaJuly 2025 Momentum & Stepwise Trade Signal Guides - baoquankhu1.vn
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Exploring Growth Potential Amid a 3.39% Upside - DirectorsTalk Interviews
Sentiment Recap: Does Akero Therapeutics Inc meet Warren Buffetts criteriaWeekly Risk Report & Smart Swing Trading Alerts - baoquankhu1.vn
Akero Therapeutics shareholders approve Novo Nordisk merger - MSN
December blockbusters push biopharma deal value to record high - BioWorld MedTech
Q4 Activity Finishes Off Stronger Biopharma M&A Year In 2025 - Citeline News & Insights
Aug Technicals: Is CKX Lands Inc a potential multi baggerMarket Activity Recap & Daily Profit Focused Stock Screening - baoquankhu1.vn
Inflation Data: Is ISPC still a buy after recent gainsJuly 2025 EndofMonth & Long-Term Safe Return Strategies - baoquankhu1.vn
Published on: 2026-01-14 06:28:29 - Bộ Nội Vụ
Insider Buy: What is Akero Therapeutics Incs revenue forecastJuly 2025 Earnings & Safe Capital Investment Plans - baoquankhu1.vn
Akero Therapeutics, Inc. (AKRO) Stock Analysis: Navigating the Biotech’s 3.39% Potential Upside - DirectorsTalk Interviews
Akero Therapeutics Inc Stock (AKRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.69%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):